Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy
| Autor: | Gregory D. Kirk, Douglas R. Richesson, Ryan P. Westergaard, Noya Galai, Shruti H. Mehta |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty Multivariate analysis Anti-HIV Agents HIV Infections Logistic regression Cohort Studies Internal medicine Antiretroviral Therapy Highly Active medicine Humans Prospective Studies Treatment Failure Prospective cohort study Substance Abuse Intravenous Generalized estimating equation business.industry Prisoners Odds ratio Middle Aged Viral Load Confidence interval Surgery Infectious Diseases Baltimore RNA Viral HIV/AIDS Female business Viral load Cohort study |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 53(7) |
| ISSN: | 1537-6591 |
| Popis: | Background. Incarceration may lead to interruptions in antiretroviral therapy (ART) for persons receiving treatment for human immunodeficiency virus (HIV) infection. We assessed whether incarceration and subsequent release were associated with virologic failure for injection drug users (IDUs) who were previously successfully treated with ART. Methods. ALIVE is a prospective, community-based cohort study of IDUs in Baltimore, Maryland. IDUs receiving ART during 1998–2009 who successfully achieved an HIV RNA level below the limit of detection (30 days was not (odds ratio, 1.4; 95% confidence interval, .8–2.6). Conclusions. Among IDUs achieving viral suppression while receiving ART, virologic failure occurred with high frequency and was strongly associated with brief incarceration. Efforts should be made to ensure continuity of care both during and after incarceration to improve treatment outcomes and prevent viral resistance in this vulnerable population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|